Company / Financials
LEXICON PHARMACEUTICALS, INC. Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.2M
FY2025 · +766.2% YoY
Net Income
-$177.1M
FY2025 · -73.7% YoY
Profit Margin
-14710.9%
FY2025 · net income / revenue
ROE
-164.7%
FY2025 · return on equity
Total Assets
$185.0M
FY2025
Total Debt
$49.4M
0.46x debt/equity
Equity
$107.5M
FY2025
ROA
-95.8%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.2M+766.2% YoYNet Income HistoryProfit after all expenses and taxes-$177.1M-73.7% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$85.0KOperating Income HistoryProfit from core business operations before interest and taxes-$171.8M-70.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$114.0M+137.1% YoYR&D Expense HistoryResearch and development spending$58.9M+11.5% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.80-29.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.80-29.0% YoY